- Home
- LSBK vs ATOS Comparison
LSBK vs ATOS Comparison
Compare LSBK & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LSBK | ATOS |
|---|---|---|
| Founded | 1891 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.0M | 100.8M |
| IPO Year | 2006 | 2012 |
Fundamental Metrics
Financial Performance| Metric | LSBK | ATOS |
|---|---|---|
| Price | $14.76 | $0.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.33 |
| AVG Volume (30 Days) | 11.5K | ★ 1.2M |
| Earning Date | 01-23-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | ★ 105.28 | N/A |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $27,774,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.24 | ★ N/A |
| Revenue Growth | ★ 9.61 | N/A |
| 52 Week Low | $11.50 | $0.55 |
| 52 Week High | $16.95 | $1.29 |
Technical Indicators
Market Signals| Indicator | LSBK | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 55.00 | 35.76 |
| Support Level | $14.53 | $0.70 |
| Resistance Level | $14.98 | $0.75 |
| Average True Range (ATR) | 0.21 | 0.05 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 34.85 | 3.13 |
Price Performance
Historical ComparisonAbout LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.